Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer

被引:10
作者
Neo, Shi Yong [1 ,2 ]
Xu, Shengli [1 ,3 ]
Chong, Joni [1 ]
Lam, Kong-Peng [1 ,4 ,5 ]
Wu, Jing [6 ,7 ]
机构
[1] Singapore Immunol Network SIgN, Agcy Sci Technol & Res ASTAR, Singapore, Singapore
[2] Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden
[3] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore
[4] Nanyang Technol Univ, Sch Biol Sci, Singapore, Singapore
[5] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore
[6] Shandong First Med Univ, Dept Pharm, Affiliated Hosp 1, Jinan, Peoples R China
[7] Shandong Prov Qianfoshan Hosp, Dept Pharm, Jinan, Peoples R China
基金
中国国家自然科学基金; 新加坡国家研究基金会; 英国医学研究理事会;
关键词
cell engineering; immunotherapy; adoptive; killer cells; natural; lymphocytes; tumor-infiltrating; receptors; chimeric antigen; CHIMERIC ANTIGEN RECEPTOR; NATURAL-KILLER-CELLS; DELTA T-CELLS; ACUTE LYMPHOBLASTIC-LEUKEMIA; IN-VIVO; NK CELLS; IMMUNOTHERAPY; EXPANSION; IMMUNOGLOBULIN; CYTOTOXICITY;
D O I
10.1136/jitc-2022-006434
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cell therapy encompasses an expanding spectrum of cell-based regimes for the treatment of human ailments, such as the use of immune cells, in particular T cells, for combating tumors and the modulation of inflammatory immune responses. In this review, we focus on cell therapy in the immuno-oncology space, which is largely driven by interests and demands from the clinics for better solutions to target various hard-to-treat cancers. We discuss recent advances in various types of cell therapies, including T cell receptor-T cells, chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes and natural killer cells. Particularly, the present review focuses on the strategies to improve therapeutic responses by either enhancing tumor recognition or the resilience of infused immune cells within tumor microenvironment. Finally, we discuss the potential of other innate or innate-like immune cell types currently being explored as promising CAR-cell alternatives that seek to address the limitations of conventional adoptive cell therapies.
引用
收藏
页数:10
相关论文
共 103 条
  • [1] γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes
    Airoldi, Irma
    Bertaina, Alice
    Prigione, Ignazia
    Zorzoli, Alessia
    Pagliara, Daria
    Cocco, Claudia
    Meazza, Raffaella
    Loiacono, Fabrizio
    Lucarelli, Barbarella
    Bernardo, Maria Ester
    Barbarito, Giulia
    Pende, Daniela
    Moretta, Alessandro
    Pistoia, Vito
    Moretta, Lorenzo
    Locatelli, Franco
    [J]. BLOOD, 2015, 125 (15) : 2349 - 2358
  • [2] Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
    Andre, Pascale
    Denis, Caroline
    Soulas, Caroline
    Bourbon-Caillet, Clarisse
    Lopez, Julie
    Arnoux, Thomas
    Blery, Mathieu
    Bonnafous, Cecile
    Gauthier, Laurent
    Morel, Ariane
    Rossi, Benjamin
    Remark, Romain
    Breso, Violette
    Bonnet, Elodie
    Habif, Guillaume
    Guia, Sophie
    Lalanne, Ana Ines
    Hoffmann, Caroline
    Lantz, Olivier
    Fayette, Jerome
    Boyer-Chammard, Agnes
    Zerbib, Robert
    Dodion, Pierre
    Ghadially, Hormas
    Jure-Kunkel, Maria
    Morel, Yannis
    Herbst, Ronald
    Narni-Mancinelli, Emilie
    Cohen, Roger B.
    Vivier, Eric
    [J]. CELL, 2018, 175 (07) : 1731 - +
  • [3] Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
    Bendle, Gavin M.
    Linnemann, Carsten
    Hooijkaas, Anna I.
    Bies, Laura
    de Witte, Moniek A.
    Jorritsma, Annelies
    Kaiser, Andrew D. M.
    Pouw, Nadine
    Debets, Reno
    Kieback, Elisa
    Uckert, Wolfgang
    Song, Ji-Ying
    Haanen, John B. A. G.
    Schumacher, Ton N. M.
    [J]. NATURE MEDICINE, 2010, 16 (05) : 565 - U98
  • [4] Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia
    Blaeschke, Franziska
    Stenger, Dana
    Kaeuferle, Theresa
    Willier, Semjon
    Lotfi, Ramin
    Kaiser, Andrew Didier
    Assenmacher, Mario
    Doering, Michaela
    Feucht, Judith
    Feuchtinger, Tobias
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (07) : 1053 - 1066
  • [5] Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review
    Brandt, Laerke J. B.
    Barnkob, Mike B.
    Michaels, Yale S.
    Heiselberg, Julia
    Barington, Torben
    [J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [6] Human natural killer cells
    Caligiuri, Michael A.
    [J]. BLOOD, 2008, 112 (03) : 461 - 469
  • [7] Localized Chemotherapy Based on Injectable Hydrogel Boosts the Antitumor Activity of Adoptively Transferred T Lymphocytes In Vivo
    Cao, Yue
    Zhou, Yuhao
    Chen, Zhixiong
    Zhang, Zhen
    Chen, Xuesi
    He, Chaoliang
    [J]. ADVANCED HEALTHCARE MATERIALS, 2021, 10 (19)
  • [8] Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation
    Capsomidis, Anna
    Benthall, Gabriel
    Van Acker, Heleen H.
    Fisher, Jonathan
    Kramer, Anne M.
    Abeln, Zarah
    Majani, Yvonne
    Gileadi, Talia
    Wallace, Rebecca
    Gustafsson, Kenth
    Flutter, Barry
    Anderson, John
    [J]. MOLECULAR THERAPY, 2018, 26 (02) : 354 - 365
  • [9] IFN gene/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment
    Catarinella, Mario
    Monestiroli, Andrea
    Escobar, Giulia
    Fiocchi, Amleto
    Ngoc Lan Tran
    Aiolfi, Roberto
    Marra, Paolo
    Esposito, Antonio
    Cipriani, Federica
    Aldrighetti, Luca
    Iannacone, Matteo
    Naldini, Luigi
    Guidotti, Luca G.
    Sitia, Giovanni
    [J]. EMBO MOLECULAR MEDICINE, 2016, 8 (02) : 155 - 170
  • [10] Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy
    Chamoto, K
    Kosaka, A
    Tsuji, T
    Matsuzaki, J
    Sato, T
    Takeshima, T
    Iwakabe, K
    Togashi, Y
    Koda, T
    Nishimura, T
    [J]. CANCER SCIENCE, 2003, 94 (10) : 924 - 928